A Systematic Review of Vascular Endothelial Growth Factor Expression As a Biomarker of Prognosis in Patients with Osteosarcoma

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2013 Apr 17

PMID 23589053

Citations 42

Authors

Ding Chen

Ye-Jia Zhang

Ke-Wei Zhu

Wan-Chun Wang

Affiliations

Soon will be listed here.

Abstract

Vascular endothelial growth factor (VEGF) plays an important role in the tumor angiogenesis, and its expression has been supposed to be a biomarker of prognosis in patients with osteosarcoma. There are many studies assessing the prognostic role of VEGF expression in osteosarcoma, and no consistent outcomes are reported. To provide a comprehensive assessment of the prognostic role of VEGF expression, we performed a systematic review and meta-analysis of published studies. We assessed the effect of VEGF expression on the overall survival rate and the disease-free survival rate by calculating the pooled odds ratio (OR) with corresponding 95 % confidence interval (95 %CI). Finally, 12 studies with a total of 559 osteosarcoma patients were included into the systematic review and meta-analysis. Compared with osteosarcoma patients with low or negative VEGF expression, patients with high VEGF expression were obviously associated with lower disease-free survival (OR=0.25, 95 %CI 0.11-0.58, P=0.001, I (2) =56.4 %). In addition, patients with high VEGF expression were obviously associated with lower overall survival (OR=0.22, 95 %CI 0.13-0.35, P<0.001, I (2) =0.0 %). Therefore, the findings from this systematic review suggest that VEGF expression is an effective biomarker of prognosis in patients with osteosarcoma.

Citing Articles

Osteosarcoma tumor microenvironment: the key for the successful development of biologically relevant 3D in vitro models.

Rodrigues J, Sarmento B, Leite Pereira C In Vitro Model. 2025; 1(1):5-27.

PMID: 39872973 PMC: 11756501. DOI: 10.1007/s44164-022-00008-x.

Proteomic and transcriptomic analyses identify apo-transcobalamin-II as a biomarker of overall survival in osteosarcoma.

Lacinski R, Dziadowicz S, Roth C, Ma L, Melemai V, Fitzpatrick B Front Oncol. 2024; 14:1417459.

PMID: 39493449 PMC: 11527601. DOI: 10.3389/fonc.2024.1417459.

Exosomes in Bone Cancer: Unveiling their Vital Role in Diagnosis, Prognosis, and Therapeutic Advancements.

Ghosh S, Mahajan A, Dey A, Rajendran R, Chowdhury A, Sen S J Cancer. 2024; 15(13):4128-4142.

PMID: 38947401 PMC: 11212077. DOI: 10.7150/jca.95709.

Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy.

Ruzzi F, Semprini M, Scalambra L, Palladini A, Angelicola S, Cappello C Int J Mol Sci. 2023; 24(16).

PMID: 37629147 PMC: 10454695. DOI: 10.3390/ijms241612963.

Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis.

Nirala B, Yamamichi T, Yustein J Int J Mol Sci. 2023; 24(14).

PMID: 37511127 PMC: 10379831. DOI: 10.3390/ijms241411367.

References

Lammli J, Fan M, Rosenthal H, Patni M, Rinehart E, Vergara G . Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma. Int Orthop. 2012; 36(11):2307-13. PMC: 3479297. DOI: 10.1007/s00264-012-1629-z. View

Ritter J, Bielack S . Osteosarcoma. Ann Oncol. 2010; 21 Suppl 7:vii320-5. DOI: 10.1093/annonc/mdq276. View

Lin F, Zheng S, Shen Z, Tang L, Chen P, Sun Y . Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma. Med Oncol. 2010; 28(2):649-53. DOI: 10.1007/s12032-010-9493-4. View

Smith R, Tang J, Tudur-Smith C, Neoptolemos J, Ghaneh P . Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer. 2011; 104(9):1440-51. PMC: 3101928. DOI: 10.1038/bjc.2011.110. View

Jung S, Moon E, Seo H, Kim J, Kim G, Kim Y . Expression and significance of TGF-beta isoform and VEGF in osteosarcoma. Orthopedics. 2005; 28(8):755-60. DOI: 10.3928/0147-7447-20050801-11. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Kaya M, Wada T, Nagoya S, Sasaki M, Matsumura T, Yamashita T . The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma. J Bone Joint Surg Br. 2009; 91(6):784-8. DOI: 10.1302/0301-620X.91B6.21853. View

Kaumaya P, Foy K . Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol. 2012; 8(8):961-87. PMC: 4591923. DOI: 10.2217/fon.12.95. View

Zhou Q, Zhu Y, Deng Z, Long H, Zhang S, Chen X . VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol. 2009; 20(1):13-9. DOI: 10.1016/j.suronc.2009.09.002. View

10.

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

11.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

12.

Chen M, Cai E, Huang J, Yu P, Li K . Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012; 21(7):1126-34. DOI: 10.1158/1055-9965.EPI-12-0020. View

13.

Rastogi S, Kumar R, Sankineani S, Marimuthu K, Rijal L, Prakash S . Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study. Int Orthop. 2012; 36(11):2315-21. PMC: 3479274. DOI: 10.1007/s00264-012-1663-x. View

14.

Peng L, Zhan P, Zhou Y, Fang W, Zhao P, Zheng Y . Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep. 2012; 39(10):9473-84. DOI: 10.1007/s11033-012-1812-8. View

15.

Niswander L, Kim S . Stratifying osteosarcoma: minimizing and maximizing therapy. Curr Oncol Rep. 2010; 12(4):266-70. PMC: 7316378. DOI: 10.1007/s11912-010-0106-3. View

16.

Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere J, Benamouzig R . Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 2006; 94(12):1823-32. PMC: 2361355. DOI: 10.1038/sj.bjc.6603176. View

17.

Chen Y, Yang Y, Yuan Z, Wang C, Shi Y . Predicting chemosensitivity in osteosarcoma prior to chemotherapy: An investigational study of biomarkers with immunohistochemistry. Oncol Lett. 2012; 3(5):1011-1016. PMC: 3389645. DOI: 10.3892/ol.2012.604. View

18.

Yang J, Yang D, Sun Y, Sun B, Wang G, Trent J . Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer. 2011; 117(21):4925-38. PMC: 3465081. DOI: 10.1002/cncr.26116. View

19.

Lugowska I, Wozniak W, Klepacka T, Michalak E, Szamotulska K . A prognostic evaluation of vascular endothelial growth factor in children and young adults with osteosarcoma. Pediatr Blood Cancer. 2011; 57(1):63-8. DOI: 10.1002/pbc.23021. View

20.

Ek E, Ojaimi J, Kitagawa Y, Choong P . Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma?. Oncol Rep. 2006; 16(1):17-23. View